BioCentury | Feb 24, 2021
Deals

Feb. 23 Quick Takes: BGI raises $300M, plus a $230M C round for Clover, Day One, Waksal’s Graviton, Asalyxa

...million in an oversubscribed series C round co-led by GL Ventures and Temasek. New investors Oceanpine Capital...
...of the $1.4 billion acquisition of CV Therapeutics by Gilead Sciences Inc. (NASDAQ:GILD) in 2009. Oceanpine Capital...
BioCentury | Aug 28, 2020
Finance

Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence

...investment bank Bloom Burton & Co. and the Montreal-based Centre for Commercialization of Cancer Immunotherapy (C3i). Oceanpine Capital...
BioCentury | Mar 25, 2020
Finance

March 24 Quick Takes: Apexigen brings series C to $123M; plus Nanjing F&S, FCA and Asieris

...the round to $123 million. The extension was led by Decheng Capital and new investor Oceanpine Capital...
BioCentury | Oct 16, 2019
Financial News

China-heavy syndicate backs $80M series B for antiviral play Ansun

...antiviral company’s long-term strategy to add Chinese investors to help it penetrate the China market. Oceanpine Capital...
BioCentury | Oct 11, 2018
Financial News

Cancer company Rgenix raises $40M series C

...million on Oct. 9 in a series C round led by Lepu Medical. New investors Oceanpine Capital...
BioCentury | May 18, 2018
Finance

Ansun’s China ambitions

...from fellow new Chinese investors Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital...
BioCentury | May 18, 2018
Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

...Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital...
BioCentury | May 14, 2018
Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

...Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital...
Items per page:
1 - 8 of 8
BioCentury | Feb 24, 2021
Deals

Feb. 23 Quick Takes: BGI raises $300M, plus a $230M C round for Clover, Day One, Waksal’s Graviton, Asalyxa

...million in an oversubscribed series C round co-led by GL Ventures and Temasek. New investors Oceanpine Capital...
...of the $1.4 billion acquisition of CV Therapeutics by Gilead Sciences Inc. (NASDAQ:GILD) in 2009. Oceanpine Capital...
BioCentury | Aug 28, 2020
Finance

Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence

...investment bank Bloom Burton & Co. and the Montreal-based Centre for Commercialization of Cancer Immunotherapy (C3i). Oceanpine Capital...
BioCentury | Mar 25, 2020
Finance

March 24 Quick Takes: Apexigen brings series C to $123M; plus Nanjing F&S, FCA and Asieris

...the round to $123 million. The extension was led by Decheng Capital and new investor Oceanpine Capital...
BioCentury | Oct 16, 2019
Financial News

China-heavy syndicate backs $80M series B for antiviral play Ansun

...antiviral company’s long-term strategy to add Chinese investors to help it penetrate the China market. Oceanpine Capital...
BioCentury | Oct 11, 2018
Financial News

Cancer company Rgenix raises $40M series C

...million on Oct. 9 in a series C round led by Lepu Medical. New investors Oceanpine Capital...
BioCentury | May 18, 2018
Finance

Ansun’s China ambitions

...from fellow new Chinese investors Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital...
BioCentury | May 18, 2018
Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

...Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital...
BioCentury | May 14, 2018
Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

...Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital...
Items per page:
1 - 8 of 8